Meeting
2021 Genitourinary Cancers Symposium
ctDNA pathogenic variants (PVs) in homologous recombination repair (HRR) genes in patients with metastatic CRPC.
Presenter
Ellen Jaeger, BS
Tulane University
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Poster Session: Prostate Cancer - Advanced Disease
Track
Prostate Cancer - Advanced
Sub Track
Translational Research
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 138)
DOI
10.1200/JCO.2021.39.6_suppl.138
Abstract #
138
Poster Bd #
Online Only
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2023 ASCO Annual Meeting
Use of circulating tumor DNA (ctDNA) to complement tumor tissue homologous recombination repair (HRR) gene alteration testing in TALAPRO-2, a phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Speaker: Arun Azad, PhD, MBBS, FRACP
Videos & Slides
2023 ASCO Annual Meeting
Phase 2 trial of pembrolizumab and olaparib (POLAR) maintenance for patients (pts) with metastatic pancreatic cancer (mPDAC): Two cohorts B non-core homologous recombination deficiency (HRD) and C exceptional response to platinum-therapy.
Speaker: Wungki Park, MD, MS
Videos & Slides
2023 ASCO Genitourinary Cancers Symposium
Real world (rw) homologous recombination repair (HRR) gene mutation testing trends in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the United States (US).
Speaker: Pedro C. Barata, MD, MSc
Videos & Slides
2022 ASCO Genitourinary Cancers Symposium
ADAM: A multicenter, non-interventional, prospective cohort study for determination of prevalence of homologous recombination repair genes mutations (HRRm) in metastatic castrate resistant prostate cancer (mCRPC)—Interim analysis.
Speaker: Boris Alekseev, MD